Barry Frankel
Gründer bei Sedor Pharmaceuticals LLC
Profil
Barry R.
Frankel is the founder of Sedor Pharmaceuticals LLC.
He is currently a Director at Galenica Pharmaceuticals, Inc. His former positions include Director at SyntheMed, Inc., Molecular Insight Pharmaceuticals, Inc., and Inspiration Biopharmaceuticals, Inc., Managing Director at BioDevelopment Ventures, and President at S.J.
Weinstein Associates, Inc. He was also an Investment Research Officer at Citibank NA (New York).
Mr. Frankel holds an MBA from the University of Pennsylvania and an undergraduate degree from Rutgers State University of New Jersey.
Aktive Positionen von Barry Frankel
| Unternehmen | Position | Beginn |
|---|---|---|
Galenica Pharmaceuticals, Inc.
 Galenica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galenica Pharmaceuticals, Inc. develops vaccines. The company was founded by Jacques Marcotte and James S. Manuso and is headquartered in Birmingham, AL. | Direktor/Vorstandsmitglied | - |
Sedor Pharmaceuticals LLC
 Sedor Pharmaceuticals LLC Financial ConglomeratesFinance Sedor Pharmaceuticals LLC is a pharmaceutical company that identifies, acquires, and develops acute care pharmaceutical assets for commercial licensing. The private company is based in Paoli, PA, and was founded by John A. Sedor and Barry R. Frankel. The company's lead product, Sesquient, has received FDA approval for the treatment of status epilepticus, and they are preparing to enter phase I development of their second product, Meloxicam for injection solubilized with betadex sulfobutyl ether sodium, for the potential treatment of acute post-surgical pain. Both products were licensed from Ligand Pharmaceuticals. The company is led by Chairman and CEO John Sedor and an experienced team of pharmaceutical professionals. John A. Sedor has been the CEO since incorporation. | Gründer | - |
Ehemalige bekannte Positionen von Barry Frankel
| Unternehmen | Position | Ende |
|---|---|---|
| BIOAFFINITY TECHNOLOGIES, INC. | Direktor/Vorstandsmitglied | 31.07.2018 |
The Frankel Group Associates LLC
 The Frankel Group Associates LLC Miscellaneous Commercial ServicesCommercial Services The Frankel Group Associates LLC provides strategic management consulting services to the life science industry. The company is headquartered in New York, NY. | Corporate Officer/Principal | 31.12.2013 |
SyntheMed, Inc.
 SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | Direktor/Vorstandsmitglied | 16.09.2011 |
| S.J. Weinstein Associates, Inc. | Präsident | 01.02.1993 |
Molecular Insight Pharmaceuticals, Inc.
 Molecular Insight Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Molecular Insight Pharmaceuticals, Inc. engages in developing and commercializing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose and treat disease. The company was founded in 1997 and the company is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Barry Frankel
| University of Pennsylvania | Masters Business Admin |
| Rutgers State University of New Jersey | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOAFFINITY TECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
SyntheMed, Inc.
SyntheMed, Inc. Medical SpecialtiesHealth Technology SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ | Health Technology |
Citibank NA (New York)
 Citibank NA (New York) Major BanksFinance Citibank NA engages in the provision of banking services. It offers retail and commercial banking; credit cards; banking, capital markets, and advisory; markets and securities services; private banking; and treasury and trade solutions. The company was founded on June 16, 1812 and is headquartered in New York, NY. | Finance |
Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Molecular Insight Pharmaceuticals, Inc. engages in developing and commercializing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose and treat disease. The company was founded in 1997 and the company is headquartered in Cambridge, MA. | Health Services |
Inspiration Biopharmaceuticals, Inc.
 Inspiration Biopharmaceuticals, Inc. Medical SpecialtiesHealth Technology Inspiration Biopharmaceuticals, Inc. produces intravenous recombinant therapies and develops non-invasive applications. It offers its products for the hemophilia community. The company was founded by Scott Donnelly Martin and John Read Taylor, Jr. on April 28, 2006 and is headquartered in Boston, MA. | Health Technology |
Galenica Pharmaceuticals, Inc.
Galenica Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galenica Pharmaceuticals, Inc. develops vaccines. The company was founded by Jacques Marcotte and James S. Manuso and is headquartered in Birmingham, AL. | Health Technology |
BioDevelopment Ventures
 BioDevelopment Ventures Investment ManagersFinance BioDevelopment Ventures (BioDevelopment Ventures) is a private equity firm. The firm is headquartered in New York. | Finance |
The Frankel Group Associates LLC
The Frankel Group Associates LLC Miscellaneous Commercial ServicesCommercial Services The Frankel Group Associates LLC provides strategic management consulting services to the life science industry. The company is headquartered in New York, NY. | Commercial Services |
| S.J. Weinstein Associates, Inc. | |
Sedor Pharmaceuticals LLC
Sedor Pharmaceuticals LLC Financial ConglomeratesFinance Sedor Pharmaceuticals LLC is a pharmaceutical company that identifies, acquires, and develops acute care pharmaceutical assets for commercial licensing. The private company is based in Paoli, PA, and was founded by John A. Sedor and Barry R. Frankel. The company's lead product, Sesquient, has received FDA approval for the treatment of status epilepticus, and they are preparing to enter phase I development of their second product, Meloxicam for injection solubilized with betadex sulfobutyl ether sodium, for the potential treatment of acute post-surgical pain. Both products were licensed from Ligand Pharmaceuticals. The company is led by Chairman and CEO John Sedor and an experienced team of pharmaceutical professionals. John A. Sedor has been the CEO since incorporation. | Finance |
